Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi, Eugenio Gaudio, Paola Bonetti, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Swiss Medical Weekly
|
April 5, 2024
Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry
Sofie Brouwers, Raphael Heimgartner, Natallia Laptseva, et al.
Hematological Oncology
|
June 3, 2022
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib
Adalgisa Condoluci, Lisa Milan, Gabriela Forestieri, et al.
Blood Advances
|
September 9, 2021
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
Alessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, et al.
Haematologica
|
February 24, 2018
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias
Bernhard Gerber, Martina Manzoni, Valeria Spina, et al.
Haematologica
|
November 10, 2018
The sympathomimetic agonist mirabegron did not lower <i>JAK2</i>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
Beatrice Drexler, Jakob R Passweg, Alexandar Tzankov, et al.
Bone Marrow Transplantation
|
November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Guido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2015
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi, Eugenio Gaudio, Paola Bonetti, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Swiss Medical Weekly
|
April 5, 2024
Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry
Sofie Brouwers, Raphael Heimgartner, Natallia Laptseva, et al.
Hematological Oncology
|
June 3, 2022
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib
Adalgisa Condoluci, Lisa Milan, Gabriela Forestieri, et al.
Blood Advances
|
September 9, 2021
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
Alessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, et al.
Haematologica
|
February 24, 2018
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias
Bernhard Gerber, Martina Manzoni, Valeria Spina, et al.
Haematologica
|
November 10, 2018
The sympathomimetic agonist mirabegron did not lower <i>JAK2</i>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
Beatrice Drexler, Jakob R Passweg, Alexandar Tzankov, et al.
Bone Marrow Transplantation
|
November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Guido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Page
of 9